Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.84 -14.4%	$2.34	$1.11 ▼ $5.00	$573.53M	1.9	1.80 million shs	3.98 million shs
CRDF Cardiff Oncology	$2.45 +0.8%	$3.45	$2.09 ▼ $5.64	$161.66M	1.54	3.26 million shs	1.01 million shs
DAWN Day One Biopharmaceuticals	$6.21 +1.1%	$6.64	$5.64 ▼ $16.76	$628.93M	-1.26	2.14 million shs	1.88 million shs
MGTX MeiraGTx	$8.34 +4.0%	$7.48	$3.85 ▼ $8.98	$644.53M	1.25	541,346 shs	423,600 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-14.42%	-20.52%	-30.57%	+42.64%	-50.93%
CRDF Cardiff Oncology	+0.82%	+0.41%	-40.68%	-10.91%	+8.89%
DAWN Day One Biopharmaceuticals	+1.14%	+7.07%	-10.39%	+0.81%	-53.69%
MGTX MeiraGTx	+3.99%	+4.91%	-6.19%	+65.48%	+97.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	3.1242 of 5 stars	3.5	2.0	0.0	3.1	3.3	0.6
CRDF Cardiff Oncology	1.7039 of 5 stars	3.4	0.0	0.0	2.2	1.7	0.6
DAWN Day One Biopharmaceuticals	2.8619 of 5 stars	3.6	3.0	0.0	3.1	2.5	0.0
MGTX MeiraGTx	4.49 of 5 stars	3.5	3.0	4.8	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.12	395.65% Upside
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	312.24% Upside
DAWN Day One Biopharmaceuticals	3.14	Buy	$25.33	307.94% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	187.77% Upside

Current Analyst Ratings Breakdown

Latest CRDF, MGTX, DAWN, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	48.39	N/A	N/A	$1.61 per share	1.14
CRDF Cardiff Oncology	$680K	239.70	N/A	N/A	$0.88 per share	2.78
DAWN Day One Biopharmaceuticals	$187.64M	3.39	N/A	N/A	$4.50 per share	1.38
MGTX MeiraGTx	$33.28M	20.14	N/A	N/A	$0.87 per share	9.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.84	N/A	N/A	N/A	N/A	-53.58%	-29.00%	N/A
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	8/14/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	21.95	N/A	-484.90%	-241.05%	-62.93%	N/A

Latest CRDF, MGTX, DAWN, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	N/A	N/A	N/A	$0.10 million	N/A
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.24	-$0.18	+$0.06	-$0.18	$12.92 million	$13.50 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
CRDF Cardiff Oncology	N/A	4.42	4.42
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
MGTX MeiraGTx	2.34	1.53	1.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CRDF Cardiff Oncology	16.29%
DAWN Day One Biopharmaceuticals	87.95%
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CRDF Cardiff Oncology	7.70%
DAWN Day One Biopharmaceuticals	6.20%
MGTX MeiraGTx	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable

CRDF, MGTX, DAWN, and AUTL Headlines

Recent News About These Companies

83,049 Shares in MeiraGTx Holdings PLC (NASDAQ:MGTX) Purchased by Informed Momentum Co LLC

2 hours ago | marketbeat.com

MeiraGTx (MGTX) to Release Earnings on Monday

August 9, 2025 | americanbankingnews.com

MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Privium Fund Management B.V. Sells 108,078 Shares of MeiraGTx Holdings PLC (NASDAQ:MGTX)

August 3, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Sees Unusually-High Trading Volume - What's Next?

July 31, 2025 | marketbeat.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) CFO Sells $204,480.00 in Stock

July 23, 2025 | marketbeat.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) Holdings Boosted by Readystate Asset Management LP

July 23, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Hits New 12-Month High - Here's What Happened

July 16, 2025 | marketbeat.com

MeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past week

July 9, 2025 | finance.yahoo.com

Insider Sell Alert: Alexandria Forbes Sells 47,500 Shares of MeiraGTx Holdings PLC

July 8, 2025 | gurufocus.com

MeiraGTx Holdings PLC News (MGTX) - Investing.com

July 3, 2025 | investing.com

MeiraGTx Holdings plc (MGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

3 Promising Genomics Stocks to Keep an Eye On in 2025

June 27, 2025 | zacks.com

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025 | globenewswire.com

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025 | globenewswire.com

FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment

May 10, 2025 | investing.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 9, 2025 | finance.yahoo.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

May 9, 2025 | globenewswire.com

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

April 29, 2025 | globenewswire.com

Richard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

April 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, MGTX, DAWN, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.84 -0.31 (-14.42%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.04 (+2.45%)

As of 07:40 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Cardiff Oncology NASDAQ:CRDF

$2.45 +0.02 (+0.82%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$2.44 -0.01 (-0.20%)

As of 07:40 AM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.21 +0.07 (+1.14%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$6.33 +0.12 (+1.93%)

As of 07:00 AM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

MeiraGTx NASDAQ:MGTX

$8.34 +0.32 (+3.99%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$8.51 +0.17 (+2.04%)

As of 07:00 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time